<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00402688</url>
  </required_header>
  <id_info>
    <org_study_id>CR012103</org_study_id>
    <secondary_id>CR012103</secondary_id>
    <nct_id>NCT00402688</nct_id>
  </id_info>
  <brief_title>An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis</brief_title>
  <official_title>A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PriCara, Unit of Ortho-McNeil, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of levofloxacin 750 mg
      for 2 weeks or 750 mg for 3 weeks, compared to levofloxacin 500 mg for 4 weeks in the
      treatment of chronic prostatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal duration of treatment for chronic prostatitis remains unclear. Historically,
      therapy for chronic prostatitis with other classes of antibacterials resulted in poor
      outcomes and prolonged time taking the medication. Levofloxacin belongs to the quinolone
      class of antibacterials and has been used to treat chronic prostatitis with 500mg of
      levofloxacin taken orally once a day for 4 weeks. This multicenter, double-blind (neither the
      patient nor the physician knows whether drug or placebo is being taken, or at what dosage),
      randomized (patients are assigned different treatments based on chance) study is designed to
      see if giving levofloxacin at a higher dose for shorter periods of time is safe and effective
      in treating chronic prostatitis. Safety analyses will involve the examination of the
      incidence, severity, and type of adverse events and changes in physical findings including
      vital signs and clinical laboratory tests. Patients will receive one of the following three
      dosing options: levofloxacin 750 mg orally administered once-a-day for 2 weeks followed by
      placebo once-a-day for two weeks for a total of 4 weeks, or levofloxacin 750 mg orally
      once-a-day for 3 weeks followed by placebo once-a-day for one week for a total of 4 weeks, or
      levofloxacin 500 mg orally once-a-day for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>Posttherapy Visit (Study Day 33-36)</time_frame>
    <description>Defined as cured or improved. Response is based on the resolution of signs and symptoms at post-therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom Relief (Resolved)</measure>
    <time_frame>Posttherapy Visit (Study Day 33-36)</time_frame>
    <description>Participants With Resolution of Prostatitis Signs and Symptoms; Resolution is defined as symptoms present (mild, moderate or severe) at Screening/Admission and absent (none) at the Posttherapy evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success (Non-Relapse) or Failure (Relapse)</measure>
    <time_frame>Poststudy Telephone contact at 6 weeks</time_frame>
    <description>Number of Clinical Successes or Failures at the 6-Week Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success (Non-Relapse) or Failure (Relapse)</measure>
    <time_frame>Poststudy Telephone contact at 3 Months</time_frame>
    <description>Number of Clinical Successes or Failures at 3 Month Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success (Non-Relapse) or Failure (Relapse)</measure>
    <time_frame>Poststudy Telephone Contact at 6 Months</time_frame>
    <description>Number of Clinical Successes or Failures at the 6-month Poststudy Telephone Contact For Participants Cured/Improved at the Posttherapy Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total NIH-CPSI Score</measure>
    <time_frame>Screening/Admission, On-Therapy, Week 3, Week 4, Posttherapy (Study Day 33-36)</time_frame>
    <description>National Institute of Health-Chronic Prostatitis Symptom Index numerically rates a total score (0-43) where 0 indicates no symptoms across any of the domains (pain or discomfort, urination, quality of life).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Prostatitis</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levofloxacin 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levofloxacin 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levofloxacin 500mg tablet once daily for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
    <description>750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
    <description>750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
    <description>500mg tablet once daily for 4 weeks.</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males 40 years of age or older

          -  A clinical diagnosis of chronic prostatitis as evidenced by the following two
             criteria: 1. Clinical signs and symptoms of prostatitis including a soft, tender
             prostate without noticeable nodularity with one or more of the following signs or
             symptoms: painful or difficult urination, suprapubic discomfort, painful ejaculation,
             low back pain, perineal discomfort, urinary frequency, urinary urgency or hesitancy,
             decreased urinary stream, urinary retention, pain on digital rectal examination,
             perineal tenderness or pain, fever, chills. 2. A history of chronic prostatitis as
             defined as: symptomatic prostatitis - a clinical diagnosis of prostatitis having been
             made for at least one previous episode that lasted four weeks, or two or more episodes
             during the previous twelve months.

        Exclusion Criteria:

          -  Any condition which may interfere with the evaluation of study drug including
             transurethral prostatectomy within six months of enrollment, the presence of a
             permanent transurethral catheter or a history of cystostomy or nephrostomy

          -  Taking hormone therapy

          -  Known prostatic carcinoma

          -  Allergy to levofloxacin, ofloxacin, ciprofloxacin, or other members of the quinolone
             class of antibacterials.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Smyrna</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbelt</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethany</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=62&amp;filename=CR012103_CSR.pdf</url>
    <description>An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>March 20, 2009</results_first_submitted>
  <results_first_submitted_qc>May 27, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2009</results_first_posted>
  <last_update_submitted>September 2, 2013</last_update_submitted>
  <last_update_submitted_qc>September 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Prostatitis</keyword>
  <keyword>Prostatitis</keyword>
  <keyword>levofloxacin</keyword>
  <keyword>Levaquin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatitis</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Levofloxacin 750mg for 2 Weeks</title>
          <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
        </group>
        <group group_id="P2">
          <title>Levofloxacin 750mg for 3 Weeks</title>
          <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
        </group>
        <group group_id="P3">
          <title>Levofloxacin 500mg for 4 Weeks</title>
          <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Culture Show Fluoroquinolone Resistance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Urine Cult. Yield Resistant to Levaquin</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Left Town and Forgot Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Levofloxacin 750mg for 2 Weeks</title>
          <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
        </group>
        <group group_id="B2">
          <title>Levofloxacin 750mg for 3 Weeks</title>
          <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
        </group>
        <group group_id="B3">
          <title>Levofloxacin 500mg for 4 Weeks</title>
          <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="81"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Success</title>
        <description>Defined as cured or improved. Response is based on the resolution of signs and symptoms at post-therapy.</description>
        <time_frame>Posttherapy Visit (Study Day 33-36)</time_frame>
        <population>Modified Intent to Treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin 750mg for 2 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 750mg for 3 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Levofloxacin 500mg for 4 Weeks</title>
            <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Defined as cured or improved. Response is based on the resolution of signs and symptoms at post-therapy.</description>
          <population>Modified Intent to Treat (mITT)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is a risk difference of 0.2.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.063</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.089</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
            <estimate_desc>Difference in success rates (levofloxacin 500mg for 4 weeks minus levofloxacin 750mg for 2 weeks ).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin is a risk difference of 0.2.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.106</ci_lower_limit>
            <ci_upper_limit>0.195</ci_upper_limit>
            <estimate_desc>Difference in success rates (levofloxacin 500mg for 4 weeks minus levofloxacin 750mg for 3 weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Relief (Resolved)</title>
        <description>Participants With Resolution of Prostatitis Signs and Symptoms; Resolution is defined as symptoms present (mild, moderate or severe) at Screening/Admission and absent (none) at the Posttherapy evaluation.</description>
        <time_frame>Posttherapy Visit (Study Day 33-36)</time_frame>
        <population>Modified Intent to Treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin 750mg for 2 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 750mg for 3 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Levofloxacin 500mg for 4 Weeks</title>
            <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Relief (Resolved)</title>
          <description>Participants With Resolution of Prostatitis Signs and Symptoms; Resolution is defined as symptoms present (mild, moderate or severe) at Screening/Admission and absent (none) at the Posttherapy evaluation.</description>
          <population>Modified Intent to Treat (mITT)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dysuria (n=35, 43, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suprapubic discomfort (n=41, 36, 45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Painful ejaculation (n=32, 39, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low back pain (n=43, 44, 44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perineal discomfort (n=40, 42, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frequency (n=58, 63, 62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency (n=48, 52, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hesitancy (n=37, 39, 54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased urinary stream (n=50, 47, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary retention (n=24, 26, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain on digital rectal examination (n=60, 59, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perineal tenderness or pain (n=44, 38, 43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n=4, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (n=5, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (n=3, 2, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success (Non-Relapse) or Failure (Relapse)</title>
        <description>Number of Clinical Successes or Failures at the 6-Week Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit</description>
        <time_frame>Poststudy Telephone contact at 6 weeks</time_frame>
        <population>Modified Intent-to-Treat Population (mITT) (Participants Cured/Improved at the Posttherapy Visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin 750mg for 2 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 750mg for 3 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Levofloxacin 500mg for 4 Weeks</title>
            <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success (Non-Relapse) or Failure (Relapse)</title>
          <description>Number of Clinical Successes or Failures at the 6-Week Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit</description>
          <population>Modified Intent-to-Treat Population (mITT) (Participants Cured/Improved at the Posttherapy Visit)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to Evaluate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success (Non-Relapse) or Failure (Relapse)</title>
        <description>Number of Clinical Successes or Failures at 3 Month Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit</description>
        <time_frame>Poststudy Telephone contact at 3 Months</time_frame>
        <population>Modified Intent to Treat (mITT) (Participants Cured/Improved at the Posttherapy Visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin 750mg for 2 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 750mg for 3 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Levofloxacin 500mg for 4 Weeks</title>
            <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success (Non-Relapse) or Failure (Relapse)</title>
          <description>Number of Clinical Successes or Failures at 3 Month Poststudy Telephone Contact for Participants Cured/Improved at the Posttherapy Visit</description>
          <population>Modified Intent to Treat (mITT) (Participants Cured/Improved at the Posttherapy Visit)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to Evaluate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success (Non-Relapse) or Failure (Relapse)</title>
        <description>Number of Clinical Successes or Failures at the 6-month Poststudy Telephone Contact For Participants Cured/Improved at the Posttherapy Visit</description>
        <time_frame>Poststudy Telephone Contact at 6 Months</time_frame>
        <population>Modified Intent to Treat (mITT) (Participants Cured/Improved at the Posttherapy Visit)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin 750mg for 2 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 750mg for 3 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Levofloxacin 500mg for 4 Weeks</title>
            <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success (Non-Relapse) or Failure (Relapse)</title>
          <description>Number of Clinical Successes or Failures at the 6-month Poststudy Telephone Contact For Participants Cured/Improved at the Posttherapy Visit</description>
          <population>Modified Intent to Treat (mITT) (Participants Cured/Improved at the Posttherapy Visit)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to Evaluate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total NIH-CPSI Score</title>
        <description>National Institute of Health-Chronic Prostatitis Symptom Index numerically rates a total score (0-43) where 0 indicates no symptoms across any of the domains (pain or discomfort, urination, quality of life).</description>
        <time_frame>Screening/Admission, On-Therapy, Week 3, Week 4, Posttherapy (Study Day 33-36)</time_frame>
        <population>Modified Intent to Treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin 750mg for 2 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
          </group>
          <group group_id="O2">
            <title>Levofloxacin 750mg for 3 Weeks</title>
            <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
          </group>
          <group group_id="O3">
            <title>Levofloxacin 500mg for 4 Weeks</title>
            <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Total NIH-CPSI Score</title>
          <description>National Institute of Health-Chronic Prostatitis Symptom Index numerically rates a total score (0-43) where 0 indicates no symptoms across any of the domains (pain or discomfort, urination, quality of life).</description>
          <population>Modified Intent to Treat (mITT)</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening/Admission (n=73, 74, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="2" upper_limit="27"/>
                    <measurement group_id="O2" value="12.0" lower_limit="3" upper_limit="27"/>
                    <measurement group_id="O3" value="12.9" lower_limit="3" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On-Therapy (n=70, 70, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O2" value="6.6" lower_limit="0" upper_limit="19"/>
                    <measurement group_id="O3" value="6.9" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (Visit 2) (n=62, 65, 68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="6.5" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O3" value="5.6" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (Visit 3) (n=53, 57, 61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="0" upper_limit="19"/>
                    <measurement group_id="O2" value="4.9" lower_limit="0" upper_limit="17"/>
                    <measurement group_id="O3" value="4.5" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posttherapy (Visit 4) (n=70, 71, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="5.0" lower_limit="0" upper_limit="21"/>
                    <measurement group_id="O3" value="4.6" lower_limit="0" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Levofloxacin 750mg for 2 Weeks</title>
          <description>levofloxacin, 750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.</description>
        </group>
        <group group_id="E2">
          <title>Levofloxacin 750mg for 3 Weeks</title>
          <description>levofloxacin, 750mg tablet once daily for 3 weeks followed by 1 week of placebo.</description>
        </group>
        <group group_id="E3">
          <title>Levofloxacin 500mg for 4 Weeks</title>
          <description>levofloxacin, 500mg tablet once daily for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>WHOART 1997</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2"/>
                <counts group_id="E2" subjects_affected="1"/>
                <counts group_id="E3" subjects_affected="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>WHOART 1997</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43"/>
                <counts group_id="E2" subjects_affected="42"/>
                <counts group_id="E3" subjects_affected="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Skeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Fascitis Plantar</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Penis Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Sweating Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Lead, Anti-Infective Franchise</name_or_title>
      <organization>Ortho-McNeil Janssen Scientific Affairs, LLC</organization>
      <phone>908-927-5220</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

